DEEP RESEARCH · ONCONIC THERAPEUTICS

Onconic Therapeutics: Zaqubo Commercialization and the Nesuparib Pipeline as Dual Growth Engines

A revenue-generating biotech combining a P-CAB cash flow engine with a synthetic-lethality oncology option

Written: 2025-12-27 · Biotech/pharmaceutical company analysis · Naver Blog

0. Bottom line first

1. Company overview: Jeil Pharma-backed fast commercialization

Official fact: Onconic Therapeutics was established on May 7, 2020 as Jeil Pharmaceutical's new-drug development subsidiary. In September 2020 it brought in global exclusive rights to Zaqubo and nesuparib from Jeil, and listed on KOSDAQ on December 19, 2024.

Official fact: The company is headquartered on Teheran-ro in Gangnam, Seoul and has an affiliated research institute in Hanam, Gyeonggi-do. The source highlights CEO John Kim's decision-making system across clinical development, business development, regulatory communication, and market-entry strategy.

Interpretation: Unlike many biotech ventures that hit bottlenecks in manufacturing, distribution, and sales after development, Onconic used Jeil's manufacturing and sales base plus co-promotion with Dong-A ST to accelerate early Zaqubo market penetration.

2. Financial analysis: the turnaround is visible in numbers

Official fact: 2024 revenue was KRW 14.8 billion and operating loss was KRW 4.8 billion. Through Q3 2025, revenue reached KRW 37.8 billion, more than 2.5 times 2024 full-year revenue, with operating profit of KRW 11.0 billion and 29% operating margin.

Interpretation: The 2025 result is not only a one-off licensing event. Product revenue and milestones are arriving together. The cash-burn risk that usually dominates biotech analysis has eased, giving the company a better base for additional trials and label expansion.

3. Zaqubo: the P-CAB commercialization engine

Official fact: Zaqubo, generic name zastaprazan, is a P-CAB treatment for GERD. The source says PPIs have unmet needs around slow onset, pre-meal dosing, short duration, and nocturnal acid breakthrough.

Official fact: Zaqubo reaches maximum blood concentration within one hour after dosing and aims for 24-hour acid suppression with once-daily administration. The source says the phase 3 trial in erosive GERD showed an eight-week cumulative healing rate above 99%.

Official fact: Zaqubo added a gastric-ulcer indication in June 2025 and is in phase 3 trials for non-erosive GERD and prevention of NSAID-induced peptic ulcer.

4. Global expansion: China, India, and Latin America first

Official fact: Onconic signed a technology-transfer agreement with Livzon Pharmaceutical Group in China worth about KRW 200 billion, including roughly KRW 20 billion upfront. The source describes Livzon as China's No. 1 company in PPI market share.

Official fact: The company also signed technology export agreements for India and 19 Latin American countries including Mexico, confirming entry into 26 countries worldwide.

Interpretation: Instead of forcing a direct U.S. or European launch, Onconic is targeting pharmerging markets where P-CAB adoption is still early. Regions with higher Helicobacter pylori infection and acid-related disease prevalence can open faster demand.

5. Nesuparib: option value from dual PARP and Tankyrase inhibition

Official fact: Nesuparib, or JPI-547, is a next-generation synthetic-lethality targeted cancer therapy inhibiting PARP-1/2 and Tankyrase-1/2. The source frames it as an attempt to overcome PARP-inhibitor resistance by also blocking Tankyrase, a Wnt-pathway regulator.

• Pancreatic cancer: In 2021, nesuparib received orphan-drug designation from the U.S. FDA and Korea's MFDS. Phase 1b/2 has been approved and is ongoing.
• Gastric cancer: On December 16, 2025, MFDS approved a phase 1b/2 clinical-trial-plan amendment for recurrent or metastatic gastric cancer. The study combines nesuparib with irinotecan and evaluates MTD, RP2D, DLT, and later ORR.
• Gastric and gastroesophageal junction cancer: Nesuparib received U.S. FDA orphan-drug designation in May 2025.
• Endometrial cancer: An investigator-led phase 2 study is ongoing in combination with Keytruda.

Official fact: The source cites the global synthetic-lethality drug market growing from about USD 3.17 billion in 2025 to USD 27.1 billion in 2035, a 21.5% CAGR.

6. Valuation variables and risks

Official fact: The source says 2025 full-year revenue guidance was raised 54% from KRW 16.2 billion to KRW 24.9 billion, but because Q3 cumulative revenue already reached KRW 37.8 billion, actual annual revenue could approach KRW 50.0 billion.

• Operating value: Zaqubo cash flow reduces the recurring equity-financing concern that often discounts biotechs.
• Pipeline value: Nesuparib's gastric-cancer trial entry and orphan-drug designations can raise the perceived probability of success.
• Clinical risk: Nesuparib remains around phase 2. The source warns that oncology candidates have roughly a 10% approval success rate from phase 1.
• Competition risk: Korea's P-CAB market is led by HK inno.N's K-CAB and Daewoong's Fexuclue. Zaqubo may need heavier marketing spend to gain share.
• Partner risk: Overseas revenue depends on partner development progress, milestones, and royalties.

7. Final view

I read Onconic as a balanced biotech: Zaqubo provides financial stability, while nesuparib carries the high-risk, high-return pipeline upside. The 2025 profit turnaround, Zaqubo's 26-country expansion, and nesuparib's gastric-cancer trial approval and orphan-drug designations are all re-rating ingredients. The discounts are equally clear: oncology clinical failure risk and intensifying P-CAB competition must be modeled separately.